CBD Reduced Rosacea-Like Inflammation in Mice by Blocking Multiple Pathways

Both CBD and metronidazole significantly inhibited redness, epidermal thickness, and mast cell infiltration in a rosacea-like mouse model. Their combination was more effective than either alone. CBD's therapeutic effect was associated with suppression of the ERK, JNK, and p38 MAPK signaling pathways and significant reduction in pro-inflammatory cytokines and chemokines.

Rosacea-like mouse model treated with CBD alone, metronidazole alone, or both in combination. Outcomes included clinical redness, histological measures (epidermal thickness, mast cell infiltration), and molecular analysis of MAPK signaling pathways and inflammatory markers.

Rosacea affects about 5.5% of the global population, and current treatments often have limited efficacy or side effects. This study provides mechanistic evidence for CBD as a potential alternative or adjunctive therapy.

While preclinical, this study identifies specific molecular pathways through which CBD may reduce skin inflammation. The synergy with an existing rosacea treatment (metronidazole) is notable, though human trials are needed before any clinical conclusions.

Mouse model only, not yet tested in humans. Rosacea was chemically induced, which may not fully replicate human disease. Dosing and formulation specifics may not translate to topical human applications. Short-term treatment without long-term follow-up.